Option chain shows key data for Ambari Brands Inc's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ambari Brands Inc.

Ambari Brands Inc (OTC:AMBBF) Stock, Option Chain

Ambari Aims To Revolutionize Manufacturing With Hydrogen

Markets

AMBBF

The global economy is changing forever.

Everything you see on supermarket shelves and at online retailers may soon be produced with clean energy exclusively. The world needs this revolution to transition to a more sustainable economy. 

It is a trillion-dollar trend unfolding right now.

Ambari Brands Aims to Drive the “Green Manufacturing” Revolution

Emerging Markets

The global manufacturing sector is undergoing a transformation.

Old methods of outsourcing production overseas without regard to their impact on the environment are on the way out.

Ambari Brands Aims to Drive the &#34;Green Manufacturing&#34; Revolution

Ambari Brands Inc

Home cultivation of recreational cannabis is <a href="https://www.growweedeasy.com/where-united-states-cannabis-legal-to-grow">permitted</a> in more than 20 US states and the District of Columbia with at least six additional states allowing it exclusively for medical marijuana patients. This represents a significant cultural shift as more Americans embrace home growing as a mainstream activity.
According to a recent survey of 961 home growers conducted by Stripe Theory on behalf of I Love Growing Marijuana (ILGM) &#8211; a community-focused cannabis seed bank &#8211; 66% of respondents said they felt empowered to grow openly thanks to relaxed cannabis regulations. These findings reveal broader cultural trends in wellness, self-sufficiency and sustainability as well as reshaping the perception of cannabis cultivation.
<h3 class="wp-block-heading">The Rise Of A Diverse Home-Growing Community</h3>
Far from outdated stereotypes, today's cannabis home growers represent a diverse and evolving demographic. 
The survey revealed that 60% are women, a figure supported by other research showing that women are <a href="https://www.benzinga.com/markets/cannabis/24/10/41478283/female-cannabis-consumers-outspend-men-how-tilray-and-high-tide-are-responding?adt_ei={{email}}">increasingly outpacing men in cannabis consumption</a>. This shift highlights a growing alignment between cannabis culture and the broader wellness movement. 
"It's inspiring to see people from all walks of life embracing home growing,&#8221; said Ernst Rustenhoven, CEO of ILGM. &#8220;The practice of cultivating your own cannabis allows people to dismantle outdated stereotypes, increase self-sufficiency, take control of their health, and create community with like-minded individuals."
<h3 class="wp-block-heading">Empowerment Through Cultivation</h3>
For many, growing marijuana at home isn't just a hobby, it's a therapeutic and empowering act.
The survey found that 57% of participants view home cultivation as a means of taking control of their health and wellness. Meanwhile, 41% described the activity as "therapeutic and stress-relieving," emphasizing its role as a form of self-care. Additionally, 38% of growers cited a sense of self-sufficiency and control as a motivating factor, with 35% cultivating at home to ensure the quality and strain selection of their cannabis.
<h3 class="wp-block-heading">Challenges And Misconceptions</h3>
Despite its increasing popularity, home cultivation still comes with challenges and misconceptions.
While 44% of respondents said the biggest myth about growing weed is that it's overly difficult or requires advanced skills. Common hurdles include managing male plants (32%), unexpected growth characteristics (24%) and germination issues (23%).
This gap in readily available resources has fostered a reliance on community support as nearly half of respondents (48%) said the home-growing community has been essential for advice and learning.
<h3 class="wp-block-heading">A Look Ahead At The Trends</h3>
The survey also shed light on emerging trends that could shape the future of cannabis cultivation. A majority of respondents (51%) prefer outdoor growing in gardens or greenhouses, reflecting a move towards natural environments. 46% said they believed organic and regenerative growing practices will become mainstream in the coming five years. These preferences align with broader cultural shifts towards sustainability and environmentally conscious living.
What&#8217;s more, changing regulations have reduced the stigma around growing pot at home in some areas. However, more than 20 states still prohibit home cultivation entirely, proof of the uneven landscape of cannabis laws across the United States.
<h3 class="wp-block-heading">A Cultural Shift</h3>
Cannabis home growing is more than a growing trend, it's a reflection of changing attitudes towards cannabis and its role in personal wellness, community building and sustainable living. As the practice gains traction, it's clear that home growers are not just cultivating plants, they're cultivating a new narrative for cannabis in America.
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Cover image made with AI

Cannabis

News

Exclusives

60% Of Cannabis Home Growers Are Women, Says Survey: A New Era In Marijuana Cultivation?

<a href="https://techcrunch.com/2024/11/19/new-in-house-chips-round-out-microsofts-portfolio/" title="https://techcrunch.com/2024/11/19/new-in-house-chips-round-out-microsofts-portfolio/">https://techcrunch.com/2024/11/19/new-in-house-chips-round-out-microsofts-portfolio/</a>

MSFT

Microsoft Unveils Azure Boost DPU, A Custom Chip For Data Processing And Security, Promising 4x Storage Performance And 3x Power Efficiency For Future Azure Servers

Nature's Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) ("Nature's Miracle" or the "Company"), a leader in vertical farming technology and infrastructure, today announced that on November 21, 2024, effective at 12:01 a.m. Eastern Time, it will effectuate a 1-for-30 reverse split of its common stock. The Company's common stock will begin trading on a split-adjusted basis when the market opens on November 21, 2024, under its current trading symbol "NMHI". The new CUSIP number of the Company's common stock following the reverse stock split will be 63903P 209.
The reverse stock split is intended, among other things, primarily to increase the bid price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Global Market.
When the reverse stock split becomes effective, every 30 shares of the Company's common stock issued and outstanding will be combined and reclassified automatically into 1 share of common stock. The reverse stock split will affect all holders of common stock uniformly and each stockholder will hold the same percentage of common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for adjustments that may result from the treatment of fractional shares. No fractional shares will be issued in connection with the reverse stock split. Any amount of fractional shares will be rounded up to the next nearest number at the participant level.

Stock Split

NMHI

Nature's Miracle Holding Announces 1-For-30 Reverse Stock Split, Will Begin Trading On A Split-Adjusted Basis When The Market Opens On November 21, 2024

Health Care

General

LFWD

Lifeward Highlights Decision By Government Of Hungary To Establish A New state Insurance Code To Provide Coverage For Exoskeleton Training For Individuals Living With Spinal Cord Injury

Barclays analyst Saket Kalia initiates coverage on Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Equal-Weight rating and announces Price Target of $81.

Price Target

Initiation

Analyst Ratings

OKTA

Barclays Initiates Coverage On Okta with Equal-Weight Rating, Announces Price Target of $81

Star Equity Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRR#NASDAQ">STRR</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.26) by 11.54 percent. The company reported quarterly sales of $13.66 million which beat the analyst consensus estimate of $13.15 million by 3.90 percent. This is a 30.93 percent increase over sales of $10.44 million the same period last year.

Earnings

STRR

Star Equity Hldgs Q3 2024 Adj EPS $(0.29) Misses $(0.26) Estimate, Sales $13.66M Beat $13.15M Estimate

Technical integration, product development, joint sales and delivery
Today at Microsoft Ignite, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc3.ai%2F&amp;esheet=54154572&amp;newsitemid=20241119179010&amp;lan=en-US&amp;anchor=C3+AI&amp;index=1&amp;md5=87749237894c224aba3035aede2f4143">C3 AI</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>), the Enterprise AI application software company, and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) announced a strategic alliance to accelerate the adoption of Enterprise AI on Microsoft Azure. The agreement marks a significant milestone in C3 AI and Microsoft's existing partnership, further combining C3 AI's Enterprise AI–native application software, including <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc3.ai%2Fc3-generative-ai%2F&amp;esheet=54154572&amp;newsitemid=20241119179010&amp;lan=en-US&amp;anchor=C3+Generative+AI&amp;index=2&amp;md5=e04bfa2d8be13aa9dacb9cb1904a4819">C3 Generative AI</a>, with Azure's robust and expansive ecosystem to the benefit of enterprises globally.

Microsoft Ignite, C3 AI And Microsoft Forge Strategic Alliance To Accelerate Adoption Of Enterprise AI On Microsoft Azure

Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(8.20) by 97.8 percent. This is a 53.85 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $8.63 million which beat the analyst consensus estimate of $8.58 million by 0.58 percent. This is a 21.17 percent decrease over sales of $10.95 million the same period last year.

DNMR

Danimer Scientific Q3 EPS $(0.18) Beats $(8.20) Estimate, Sales $8.63M Beat $8.58M Estimate

Buybacks

BlackLine Board Authorized Repurchase Of Up To $200M

XPON

Expion360 Says Recently Added New OEMs And One Distributor; Says New Relationships Are Expected To Add Incremental Revenue For Q4 And Est. $5M For 2025

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

LQR House Approves $1M Bitcoin Purchase As Treasury Reserve And Plans To Retain Up To $10M In Crypto Payments From CWSpirits.com, Reflecting Confidence In Digital Assets' Long-Term Potential

Leerink Partners analyst Thomas Smith upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Market Perform to Outperform and raises the price target from $2 to $7.

Upgrades

ACRS

Leerink Partners Upgrades Aclaris Therapeutics to Outperform, Raises Price Target to $7

ServiceNow And Microsoft Expand Alliance To Modernize Front-Office Processes With Copilot And AI Agents, Enhancing Workflow Integration And Self-Service Capabilities Across Microsoft Applications

Benchmark analyst Todd Brooks reiterates Lancaster Colony (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>) with a Hold.

Reiteration

LANC

Benchmark Reiterates Hold on Lancaster Colony

PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists
PRECICE is exclusively using ProSense&#xAE; to treat all 233 Luminal A and B patients &gt;50 years of age with early-stage breast cancer, a wider population of patients than ICE3 &nbsp;
Article published in European Journal of Cancer Prevention describes the PRECICE study and presents the role of cryoablation in the move toward de-escalation of surgical treatment
CAESAREA, Israel, Nov. 19, 2024 /PRNewswire/ -- <a href="https://icecure-medical.com/">IceCure Medical Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an <a href="https://journals.lww.com/eurjcancerprev/citation/9900/cryoablation_of_early_breast_cancer__the_challenge.185.aspx">article</a>&nbsp;titled "Cryoablation of early breast cancer: the challenge towards de-escalation of surgical treatment" in the European Journal of Cancer Prevention.
The article, authored by breast surgeons and interventional radiologists including Director of Interventional Radiology at the European Institute of Oncology in Milan, Italy, Franco Orsi, MD, presents a review of recent studies and literature on cryoablation of breast cancer, stating:
"The scientific assumption moving researchers is that cryoablation could represent a precise and safe alternative to the surgery itself for a selected subgroup of women."
The article highlights the Percutaneous Cryoablation of Low-risk Early Breast Cancer (<a href="https://clinicaltrials.gov/study/NCT06300125">PRECICE</a>) study, led by Principal Investigator, Dr. Orsi. PRECICE is an independent prospective observational 233 patient study that has commenced the enrollment of women 50 years of age and older with unifocal, small (up to 15 mm in diameter), clinically node-negative, luminal A and B breast cancer.
The PRECICE study, which will exclusively use ProSense&#xAE; to conduct all procedures, will evaluate the technical effectiveness of cryoablation with a median follow-up of five years (with early primary and secondary outcomes after three years). The procedure failure rate will be evaluated for possible residual tumor by mammography, ultrasound, and nuclear MRI at two months before radiotherapy and six months after radiotherapy. If relapse is suspected, an image-guided breast biopsy will be performed. Additional endpoints including quality of life, psychological impact, and economic outcomes will also be evaluated.

Biotech

Global

ICCM

IceCure's ProSense Chosen For Breast Cryoablation Study Led By The European Institute Of Oncology With Sponsorship From The Italian Ministry Of Health

BEAT

HeartBeam Unveils Data At AHA 2024 For Portable Credit Card-Sized ECG Device; Studies Demonstrate Comparable Arrhythmia Detection To Standard ECGs And Highlight Remote Chest Pain Evaluation To Reduce Heart Attack Care Delays

Lennar To Acquire Rausch Coleman Homes, Terms Not Disclosed

Benchmark analyst Mark Palmer reiterates i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) with a Buy and maintains $33 price target.

IIIV

Benchmark Reiterates Buy on i3 Verticals, Maintains $33 Price Target

Macro Economic Events

Econ #s

Economics

USA Housing Starts (MoM) For October -3.1%; -1.9% Prior

USA Housing Starts For October 1.311M Vs 1.340M Est.; 1.353M Prior

Abcourt Mines GAAP EPS of -C$0.01

Press Releases

Ambari Brands Completes AI Beauty App, Scarlett

Ambari Brands Appoints New CEO

CSE:AMB

Comments

Ambari Brands Inc

Ambari Brands Inc (AMBBF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga